| Literature DB >> 20163915 |
Manabu Onimaru1, Kenoki Ohuchida, Eishi Nagai, Kazuhiro Mizumoto, Takuya Egami, Lin Cui, Norihiro Sato, Junji Uchino, Koichi Takayama, Makoto Hashizume, Masao Tanaka.
Abstract
To overcome the limited clinical efficacy of conditionally replicative adenoviruses (CRAds), we investigated the effects of combination therapy with gemcitabine (GEM) and the hTERT-promoter-dependent CRAd (hTERT-CRAd), Ad5/3hTERTE1. This combination therapy exhibited enhanced cytotoxic effects on pancreatic cancer both in vitro and in vivo. Furthermore, we revealed that this enhancement effect was due to the multiple bidirectional interactions between hTERT-CRAd and GEM. The GEM-sensitizing effect of E1 expression derived from hTERT-CRAd, and the enhancement effect by GEM on hTERT promoter activity which led to the increase of adenovirus E1 and viral infectivity. This combination therapy may be a promising therapeutic approach for pancreatic cancer. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20163915 DOI： 10.1016/j.canlet.2010.01.034
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679